KholleKhokk

VIR - the fundamental play

ロング
NASDAQ:VIR   Vir Biotechnology, Inc.
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!

And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current market cap of a company is HUGE misspricing.

免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。